JnJ, Legend expanding cell therapy capacity.

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

We've had Eye's On the JP Morgan Healthcare Conference, Lifesciences 2024 restructuring stats, and some new drug development partnerships.

Check out the final listings of FDA NDA and BLA approvals for 2024.

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

We've had our Eyes On some of the latest Pharmaceutical news including approvals, partnering, mergers, research programs, and

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...

We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?

Check out this Top Drugs of 2023 list with links to interesting reports in PharmaTell Studio. Contact us for a trial.

We've been keeping Eyes On Deals & Raises in the BioPharma sector for the first quarter of 2024. Things seem to be heating-up ...

Lately we've been keeping Eyes On the corporate restructuring in the BioPharma sector. We've seen Big Pharma and BioTech refocusing ...

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...

2024 is off to a busy start with M&A activities highlighted at the JP Morgan Healthcare Conference, plus another Genetic Medicines approval.

Following up on our previous post about Gene Therapies, we are sharing data on Genetic Medicines in development - pipelines, targets, dates

We've been keeping Eyes On the Gene Therapy area - and thought we would post some general information about the area ...

The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and

Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.

While we've been curating 3Q23 Results reports, we've had eyes on drug approvals, Business Development activities, & even some patent ...